Mencari ubat atas namanya

Safinamide Mesylate dan Triavil

Penentuan interaksi Safinamide Mesylate dan Triavil dan kemungkinan pengambilan ubat-ubat itu secara bersama-sama.

Hasil pemeriksaan:

Safinamide Mesylate <> Triavil

Relevan: 21.08.2022 Pengulas: MD P.M. Shkutko, in

Dalam pangkalan rujukan rasmi yang digunakan untuk membuat perkhidmatan ini, telah didapati interaksi yang dicatat secara statistik berasaskan oleh hasil penyelidikan, yang boleh membawa pada akibat negatif untuk kesihatan pesakit, atau pun meningkatkan kesan positif timbal balik. Dikehendaki rundingan doktor untuk menyelesaikan perkara pengambilan ubat-ubatan secara bersama-sama.

Pengguna:

Menggunakan safinamide bersama-sama dengan amitriptyline boleh meningkatkan risiko yang jarang tapi serius keadaan yang disebut serotonin sindrom, yang mungkin termasuk gejala-gejala seperti kebingungan, halusinasi, kejang, melampau perubahan dalam tekanan darah, peningkatan detak jantung, demam, berpeluh berlebihan, atau menggigil gemetar, penglihatan kabur, kekejangan otot atau kekakuan, gegaran, ketiadaan koordinasi, perut kejang, mual, muntah, dan diare. Doktor anda mungkin dapat menetapkan alternatif yang tidak berinteraksi, atau anda mungkin perlu lebih kerap pemantauan aman untuk menggunakan kedua-dua ubat-ubatan. Bicaralah dengan doktermu jika kamu memiliki beberapa pertanyaan atau kekhawatiran. Ia adalah penting untuk memberitahu anda dokter tentang semua yang lain ubat-ubatan anda menggunakan, termasuk vitamin dan herba. Jangan berhenti menggunakan mana-mana ubat-ubatan tanpa berbicara dengan anda, doktor.

Profesional:

DISARANKAN: Dengan menghalang serotonin metabolisme, monoamine oxidase (MAOIs), termasuk safinamide, mungkin kekuasaan farmakologis aktiviti serotonin agen termasuk serotonin undang-undang ujian reuptake inhibitor (SNRIs), St. John, cyclobenzaprine, trazodone, dan tricyclic dan tetracyclic antidepresan. Hasilnya mungkin peningkatan risiko serotonin sindrom, yang jarang tapi serius dan membawa maut keadaan berpikir untuk hasil dari hyperstimulation dari batang otak 5-HT1A dan 2A reseptor. Secara klinis, interaksi telah dilaporkan terutamanya di pasien yang diobati dengan MAOIs (termasuk berbalik, berbalik, terpilih, dan nonselective) dan tricyclic antidepresan, terutama imipramine dan clomipramine, yang adalah yang paling kuat reuptake inhibitor kelas. Gejala serotonin sindrom mungkin termasuk mental perubahan status seperti cepat marah, diubah kesadaran, kekeliruan, halusinasi, dan koma; autisme disfungsi seperti tachycardia, hyperthermia, diaphoresis, menggigil, tekanan darah kelabilan, dan mydriasis; saraf kelainan seperti hyperreflexia, myoclonus, gegaran, ketegaran, dan ataxia; dan pencernaan gejala-gejala seperti kekejangan perut, mual, muntah, dan diare.

PENGURUSAN: Coadministration dari safinamide dengan ini serotonin agen dianggap disarankan.

Sumber

"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.
Levy AB, Bucher P, Votolato N "Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment." Can J Psychiatry 30 (1985): 434-6
Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5
"Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.
Dardennes RM, Even C, Ballon N, Bange F "Serotonin syndrome caused by a clomipramine-moclobemide interaction." J Clin Psychiatry 59 (1998): 382-3
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30
Bem JL, Peck R "Dextromethorphan. An overview of safety issues." Drug Saf 7 (1992): 190-9
Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD "Toxic interaction of venlafaxine and isocarboxazide." Lancet 346 (1995): 1298-9
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20
Heisler MA, Guidry JR, Arnecke B "Serotonin syndrome induced by administration of venlafaxine and phenelzine." Ann Pharmacother 30 (1996): 84
Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1
"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.
Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.
Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):
Sovner R, Wolfe J "Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid ." N Engl J Med 319 (1988): 1671
"Product Information. Methylene Blue (methylene blue)." American Regent Laboratories Inc, Shirley, NY.
White K, Pistole T, Boyd JL "Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study." Am J Psychiatry 137 (1980): 1422-5
Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1
Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5
Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62
"Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Rivers N, Horner B "Possible lethal reaction between nardil and dextromethorphan." Can Med Assoc J 103 (1970): 85
Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822
Kay DW, Garside RF, Fahy TJ "A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms." Br J Psychiatry 123 (1973): 63-7
Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6
Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23
Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK "Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports." Neurology 51 (1998): 274-6
"Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.
"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.
Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311
"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
Staufenberg EF, Tantam D "Malignant hyperpyrexia syndrome in combined treatment." Br J Psychiatry 154 (1989): 577-8
"Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
Feighner JP, Herbstein J, Damlouji N "Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression." J Clin Psychiatry 46 (1985): 206-9
Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8
Tackley RM, Tregaskis B "Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction." Anaesthesia 42 (1987): 760-3
"Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7
Thomas JM, Rubin EH "Case report of a toxic reaction from a combination of tryptophan and phenelzine." Am J Psychiatry 141 (1984): 281-3
Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5
Graham PM, Potter JM, Paterson J "Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction." Lancet 2 (1982): 440
Pope HG Jr, Jonas JM, Hudson JI, Kafka MP "Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan." Am J Psychiatry 142 (1985): 491-2
Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
Joffe RT, Post RM, Uhde TW "Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine." Arch Gen Psychiatry 42 (1985): 738
Pascual J, Combarros O, Berciano J "Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment." Clin Neuropharmacol 10 (1987): 565-7
Brubacher JR, Hoffman RS, Lurin MJ "Serotonin syndrome from venlafaxine-tranylcypromine interaction." Vet Hum Toxicol 38 (1996): 358-61
Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8
Jacob JE, Wagner ML, Sage JI "Safety of selegiline with cold medications." Ann Pharmacother 37 (2003): 438-41
"Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.
"Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.
Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
Cetaruk EW, Aaron CK "Hazards of nonprescription medications." Emerg Med Clin North Am 12 (1994): 483-510
Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11
Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5
"Product Information. Manerix (moclobemide)." Hoffmann-La Roche Limited, Mississauga, IA.
Lader M "Combined use of tricyclic antidepressants and monoamine oxidase inhibitors." J Clin Psychiatry 44 (1983): 20-4
Diamond S "The use of sumatriptan in patients on monoamine oxidase inhibitors." Neurology 45 (1995): 1039-40
"Product Information. Eldepryl (selegiline)." Somerset Pharmaceuticals Inc, Tampa, FL.
Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):
Cerner Multum, Inc. "Australian Product Information." O 0
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
"Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Ketter TA, Post RM, Parekh PI, Worthington K "Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression." J Clin Psychiatry 56 (1995): 471-5
Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5
Yatham LN, Barry S, Mobayed M, Dinan TG "Is the carbamazepine-phenelzine combination safe?." Am J Psychiatry 147 (1990): 367
"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.
Zetin M "Combined use of trimipramine and phenelzine in depression." J Nerv Ment Dis 170 (1982): 246-7
"Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Waghray SN, Francis K "Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics." J R Soc Med 77 (1984): 346
de la Fuente JR, Berlanga C, Leon-Andrade C "Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports." J Clin Psychiatry 47 (1986): 40-1
Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2
"Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8
Lydiard RB, White D, Harvey B, Taylor A "Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine." J Clin Psychopharmacol 7 (1987): 360
Weiner LA, Smythe M, Cisek J "Serotonin syndrome secondary to phenelzine-venlafaxine interaction." Pharmacotherapy 18 (1998): 399-403
White K, Simpson G "Combined MAOI-tricyclic antidepressant treatment: a reevaluation." J Clin Psychopharmacol 1 (1981): 264-82
Otte W, Birkenhager TK, van den Broek WW "Fatal interaction between tranylcypromine and imipramine." Eur Psychiatry 18 (2003): 264-5
Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20